GSK opens new manufacturing plants in Singapore
pharmafile | July 5, 2019 | News story | Manufacturing and Production | Asia, HIV, Singapore, anaemia, facilities, manufacturing, pharma
British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore.
The UK firm has also expanded facilities at its Jurong site, as part of an effort to “accelerate the supply of new breakthrough medicines to patients globally.”
The $96 million investment will see GSK employ a process called ‘continuous manufacturing’ with the aim of reducing production time and thus enabling faster supply of medicines across the globe.
The new facilities will be focused on manufacturing active pharmaceutical ingredients (APIs) for HIV drugs and the anaemia therapy Daprodustat.
“Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector,” said Mr Lim Hock Heng, vice-president and site director at GSK’s Pharmaceuticals Supply Chain Singapore.
“Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines.”
Louis Goss
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Ironic Biotech announces $1m funding to develop iron deficiency and anaemia treatment
Swedish biotech startup Ironic Biotech has announced that it has successfully closed a pre-seed funding …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …